Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity.
Opioids have been discovered to have Toll-like receptor (TLR) activity, beyond actions at classical opioid receptors. This raises the question whether other pharmacotherapies for pain control may also possess TLR activity, contributing to or opposing their clinical effects. We document that tricyclics can alter TLR4 and TLR2 signaling. In silico simulations revealed that several tricyclics docked to the same binding pocket on the TLR accessory protein, myeloid differentiation protein 2 (MD-2), as do opioids. Eight tricyclics were tested for effects on TLR4 signaling in HEK293 cells over-expressing human TLR4. Six exhibited mild (desipramine), moderate (mianserin, cyclobenzaprine, imiprimine, ketotifen) or strong (amitriptyline) TLR4 inhibition, and no TLR4 activation. In contrast, carbamazepine and oxcarbazepine exhibited mild and strong TLR4 activation, respectively, and no TLR4 inhibition. Amitriptyline but not carbamazepine also significantly inhibited TLR2 signaling in a comparable cell line. Live imaging of TLR4 activation in RAW264.7 cells and TLR4-dependent interleukin-1 release from BV-2 microglia revealed that amitriptyline blocked TLR4 signaling. Lastly, tricyclics with no (carbamazepine), moderate (cyclobenzeprine), and strong (amitriptyline) TLR4 inhibition were tested intrathecally (rats) and amitriptyline tested systemically in wildtype and knockout mice (TLR4 or MyD88). While tricyclics had no effect on basal pain responsivity, they potentiated morphine analgesia in rank-order with their potency as TLR4 inhibitors. This occurred in a TLR4/MyD88-dependent manner as no potentiation of morphine analgesia by amitriptyline occurred in these knockout mice. This suggests that TLR2 and TLR4 inhibition, possibly by interactions with MD2, contributes to effects of tricyclics in vivo. These studies provide converging lines of evidence that several tricyclics or their active metabolites may exert their biological actions, in part, via modulation of TLR4 and TLR2 signaling and suggest that inhibition of TLR4 and TLR2 signaling may potentially contribute to the efficacy of tricyclics in treating chronic pain and enhancing the analgesic efficacy of opioids.
Hutchinson
M R
MR
Department of Psychology and The Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Loram
L C
LC
Zhang
Y
Y
Shridhar
M
M
Rezvani
N
N
Berkelhammer
D
D
Phipps
S
S
Foster
P S
PS
Landgraf
K
K
Falke
J J
JJ
Rice
K C
KC
Maier
S F
SF
Yin
H
H
Watkins
L R
LR
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology*; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D008024:Ligands; D051218:Lymphocyte Antigen 96 / Q000737:chemistry / Q000502:physiology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D017628:Microglia / Q000187:drug effects / Q000378:metabolism; D008958:Models, Molecular; D009020:Morphine / Q000494:pharmacology; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics; D010147:Pain Measurement; D011485:Protein Binding; D051381:Rats; D015398:Signal Transduction; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology; D051197:Toll-Like Receptor 4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D051193:Toll-Like Receptors / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000701:Analgesics, Opioid; D006575:Heterocyclic Compounds, 3-Ring; D007375:Interleukin-1; C495377:LY96 protein, human; D008024:Ligands; D051218:Lymphocyte Antigen 96; C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha; D009020:Morphine
Neurosci Res. 2009 Jan;63(1):42-6
18992286
ScientificWorldJournal. 2007 Nov 02;7:98-111
17982582
J Biol Chem. 2004 May 7;279(19):19764-74
14998994
Pharmacol Res. 2003 Aug;48(2):157-65
12798668
Eur J Immunol. 2003 Mar;33(3):597-605
12616480
Biochem Biophys Res Commun. 2009 Jan 23;378(4):857-61
19071087
Semin Immunol. 2007 Feb;19(1):3-10
17275324
Pain. 1995 Oct;63(1):136
8577485
Trends Neurosci. 2005 Dec;28(12):661-9
16246435
Brain Behav Immun. 2009 Feb;23(2):240-50
18938237
Life Sci. 1986 Jan 27;38(4):357-63
3945166
Epilepsy Res. 2006 Jun;69(3):273-94
16621450
Eur J Neurosci. 2000 Dec;12(12):4331-7
11122343
J Biol Chem. 2007 May 18;282(20):14975-83
17355971
Anesthesiology. 1995 Nov;83(5):1046-54
7486155
J Leukoc Biol. 2009 Jun;85(6):966-77
19289601
Anesthesiology. 1995 Nov;83(5):1036-45
7486154
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16176-81
17911247
Br J Pharmacol. 1998 Jun;124(4):669-74
9690858
Innate Immun. 2009 Feb;15(1):33-41
19201823
Pain. 1999 Apr;80(3):643-653
10342426
Toxicology. 2008 Aug 19;250(1):9-14
18606486
Pain. 1996 Dec;68(2-3):217-27
9121808
Nature. 2009 Apr 30;458(7242):1191-5
19252480
Brain Behav Immun. 2010 Jan;24(1):83-95
19679181
Brain Behav Immun. 2008 Nov;22(8):1178-89
18599265
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005454
17943857
Brain Behav Immun. 2008 Nov;22(8):1248-56
18706994
J Immunol. 2001 Feb 1;166(3):1938-44
11160242
J Physiol Pharmacol. 2008 Mar;59(1):153-62
18441395
Int J Neuropsychopharmacol. 2006 Feb;9(1):27-35
15963243
Biochem Biophys Res Commun. 2010 Jan 1;391(1):426-30
19914204
Chembiochem. 2009 Mar 2;10(4):645-9
19184989
Pain. 1988 Jan;32(1):77-88
3340425
Surg Infect (Larchmt). 2007 Feb;8(1):91-106
17381401
Neuropharmacology. 2008 Oct;55(5):826-34
18639562
Immunopharmacology. 1996 Aug;34(1):27-37
8880223
Pain. 2006 Sep;124(1-2):77-86
16697108
Trends Pharmacol Sci. 2009 Nov;30(11):581-91
19762094
Neuroscience. 2010 Jan 20;165(2):569-83
19833175
Lab Invest. 2006 Jan;86(1):9-22
16357866
Int J Immunopharmacol. 1999 Oct;21(10):663-73
12609461
Clin Exp Pharmacol Physiol. 2009 Mar;36(3):297-303
18986328
J Pharmacol Sci. 2007 May;104(1):61-72
17510525
Drugs. 2008;68(18):2611-32
19093703
Trends Pharmacol Sci. 2006 Jul;27(7):348-54
16762426
Biochem Pharmacol. 2002 Apr 15;63(8):1507-16
11996893
Nat Rev Neurosci. 2009 Jan;10(1):23-36
19096368
Neurosci Res. 2001 Mar;39(3):281-6
11248367
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5856-61
15809417
Eur J Neurosci. 2008 Jul;28(1):20-9
18662331
JAMA. 2009 Jan 14;301(2):198-209
19141768
J Endotoxin Res. 2000;6(5):401-5
11521063
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jan;91(1):2-7
11174562